Go Pro

McKesson (MCK) Stock Forecast & Price Target

McKesson logo
$856.52 -10.12 (-1.17%)
Closing price 03:59 PM Eastern
Extended Trading
$856.56 +0.04 (+0.00%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

McKesson - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Sell
0
Hold
4
Buy
14

Based on 18 Wall Street analysts who have issued ratings for McKesson in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 18 analysts, 4 have given a hold rating, and 14 have given a buy rating for MCK.

Consensus Price Target

$973.44
13.65% Upside
According to the 18 analysts' twelve-month price targets for McKesson, the average price target is $973.44. The highest price target for MCK is $1,085.00, while the lowest price target for MCK is $845.00. The average price target represents a forecasted upside of 13.65% from the current price of $856.52.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for MCK and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for McKesson and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MCK Analyst Ratings Over Time

TypeCurrent Forecast
9/28/25 to 9/28/26
1 Month Ago
8/29/25 to 8/29/26
3 Months Ago
6/30/25 to 6/30/26
1 Year Ago
9/28/24 to 9/28/25
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
14 Buy rating(s)
14 Buy rating(s)
14 Buy rating(s)
11 Buy rating(s)
Hold
4 Hold rating(s)
4 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$973.44$973.44$960.53$829.08
Forecasted Upside13.65% Upside8.69% Upside26.82% Upside8.97% Upside
Consensus RatingModerate BuyModerate BuyModerate BuyModerate Buy

MCK Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

MCK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

McKesson Stock vs. The Competition

TypeMcKessonHealthcare CompaniesBroader Market
Consensus Rating Score
2.78
2.31
2.53
Consensus RatingModerate BuyHoldModerate Buy
Predicted Upside12.33% Upside808.13% Upside19.20% Upside
News Sentiment Rating
Positive News

See Recent MCK News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
9/14/2026
Ryan Halsted
Ryan Halsted
Not Rated
Reiterated RatingSector Perform$845.00-5.64%
9/4/2026
Weiss Ratings logo
Weiss Ratings
5 of 5 stars
 UpgradeBuy (B-) ➝ Buy (B)
8/19/2026
Barclays PLC logo
Barclays
3 of 5 stars
Boost TargetOverweight$925.00 ➝ $1,000.00+14.98%
8/11/2026Boost TargetEqual Weight$812.00 ➝ $933.00+6.26%
8/7/2026 Reiterated RatingOverweight
8/6/2026 Set Target$1,015.00+20.43%
8/6/2026 Reiterated RatingOutperform
8/6/2026Boost TargetBuy$989.00 ➝ $1,006.00+15.47%
8/6/2026Boost TargetBuy$1,050.00 ➝ $1,080.00+23.97%
7/24/2026Boost TargetBuy$945.00 ➝ $1,000.00+21.26%
5/8/2026 Reiterated RatingBuy$875.00+15.73%
5/8/2026Lower TargetOverweight$1,107.00 ➝ $1,015.00+37.07%
4/28/2026Initiated CoverageOutperform
4/6/2026Lower TargetBuy$1,040.00 ➝ $1,000.00+16.29%
3/5/2026 Set Target$970.00+4.12%
3/5/2026Reiterated RatingOutperform$1,085.00+16.60%
2/5/2026Boost TargetNeutral$880.00 ➝ $885.00+7.98%
11/25/2025 DowngradeStrong-Buy ➝ Hold
10/13/2025Boost TargetBuy$820.00 ➝ $900.00+17.07%
4/4/2025DowngradeModerate Buy ➝ Hold

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 09:03 PM ET.


Should I Buy McKesson Stock? MCK Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, September 26, 2026. Please send any questions or comments about these McKesson pros and cons to contact@marketbeat.com.

McKesson
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in McKesson Co.:

  • McKesson Co. recently reported first-quarter fiscal 2027 results where it beat consensus estimates, posting earnings per share of $9.93 against an expected $9.56 and generating revenue of $105.38 billion, which exceeded the $103.88 billion forecast and represented a 7.7% year-over-year increase.
  • The company has strengthened its financial outlook by raising its full-year fiscal 2027 adjusted earnings per share guidance to a range of $44.20 to $45.00, a move that analysts suggest supports the current valuation and indicates confidence in continued operational expansion.
  • Wall Street maintains a positive stance on the stock, with a consensus rating of Moderate Buy and an average price target of $973.44, which implies significant upside potential from the current stock price of $866.56.
  • McKesson Co. recently increased its quarterly dividend to $0.94 per share, representing an annualized yield of approximately 0.43% and signaling a commitment to returning capital to shareholders while maintaining a low payout ratio of 10.06%.
  • The stock exhibits a low beta of 0.30, meaning it is significantly less volatile than the broader market, which can provide a defensive characteristic for investors seeking stability in their healthcare portfolio allocations.

McKesson
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in McKesson Co. for these reasons:

  • McKesson Co. is currently navigating a confirmed cyberattack that has resulted in data theft affecting oncology and multispecialty customers, creating potential legal, operational, and reputational risks that could impact future earnings.
  • Corporate insiders have been net sellers recently, with CEO Brian Tyler selling 8,463 shares in July 2026 and Director Bradley Lerman selling 301 shares in August 2026, which may signal a lack of confidence in the stock's near-term performance.
  • The company's negative return on equity of 253.21% in the most recent quarter, despite positive net margins, suggests significant leverage or accounting complexities that may concern value-focused investors regarding the efficiency of capital deployment.
  • Short interest has increased in recent months, with shares shorted rising to 2.9 million as of September 2026, indicating that a growing number of traders are betting against the stock's price appreciation.
  • Some analysts, such as those at Royal Bank of Canada, have set price targets below the current market price, with a target of $845.00, suggesting that the stock may be overvalued relative to their fundamental models.

MCK Forecast - Frequently Asked Questions

According to the research reports of 18 Wall Street equities research analysts, the average twelve-month stock price forecast for McKesson is $973.44, with a high forecast of $1,085.00 and a low forecast of $845.00.

18 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for McKesson in the last twelve months. There are currently 4 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" MCK shares.

According to analysts, McKesson's stock has a predicted upside of 13.65% based on their 12-month stock forecasts.

Over the previous 90 days, McKesson's stock had 1 upgrade and 1 downgrade by analysts.

McKesson has been rated by research analysts at Barclays, Citigroup, Evercore, Morgan Stanley, Robert W. Baird, Royal Bank Of Canada, TD Cowen, UBS Group, Weiss Ratings, and Wells Fargo & Company in the past 90 days.

Analysts like McKesson more than other "healthcare" companies. The consensus rating for McKesson is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how MCK compares to other companies.


MarketBeat monitors more than a dozen sources for McKesson analyst ratings, with the most recent rating issued on 9/14/2026.
From Our Partners